TALEN-mediated inactivation of PD-1 in tumor-reactive lymphocytes promotes intratumoral T cell persistence and rejection of established tumors

Running title: Pdcd1 gene inactivation in tumor-reactive lymphocytes

Keywords: checkpoints inhibitors, gene editing, tumor-reactive lymphocytes

PRECIS: This proof of concept study demonstrates that advanced adoptive T cell therapies for cancer can be enhanced by genomic editing strategies to bypass immune checkpoints.

Laurie Menger 1; Anna Sledzinska 1; Katharina Bergerhoff 1; Frederick Arce Vargas 1; Julianne Smith 2; Laurent Poirot 2; Martin Pule 1; Javier Herrero 1,3; Karl S. Peggs 1* and Sergio A. Quezada 1*

1Cancer Immunology Unit, Research Department of Haematology, University College London Cancer Institute, London, UK; 2Cellectis, Paris, France; 3Bill Lyons Informatics Centre, University College London Cancer Institute, London, UK.

*K.S.P. and S.A.Q. are co-corresponding authors

Correspondence to:

Sergio A. Quezada, Ph.D and Karl S. Peggs, M.D., Ph.D.
Cancer Immunology Unit
Research Department of Haematology
UCL Cancer Institute
University College London
s.quezada@ucl.ac.uk
karl.pegawai@ucl.ac.uk

Competing interests: JS and LP are Cellectis employees.
Abstract

Despite the promising efficacy of adoptive cell therapies (ACT) in melanoma, complete response rates remain relatively low and outcomes in other cancers are less impressive. The immunosuppressive nature of the tumor microenvironment and the expression of immune-inhibitory ligands, such as PD-L1/CD274 by the tumor and stroma are considered key factors limiting efficacy. The addition of checkpoint inhibitors (CPI) to ACT protocols bypasses some mechanisms of immunosuppression, but associated toxicities remain a significant concern. To overcome PD-L1-mediated immunosuppression and reduce CPI-associated toxicities, we used TALEN technology to render tumor-reactive T cells resistant to PD-1 signaling. Here we demonstrate that inactivation of PD-1 in melanoma-reactive CD8+ T cells and in fibrosarcoma-reactive polyclonal T cells enhanced the persistence of PD-1 gene-modified T cells at the tumor site and increased tumor control. These results illustrate the feasibility and potency of approaches incorporating advanced gene-editing technologies into ACT protocols to silence immune checkpoints, as a strategy to overcome locally active immune escape pathways.
Introduction

Adoptive T cell therapy (ACT) using autologous tumor-infiltrating lymphocytes (TILs) or T cells redirected to the tumor by chimeric antigen receptors (CARs) can mediate substantial regression of human cancers (1). Whilst multiple early-phase studies using ACT have demonstrated durable responses which correlate with persistence of the transferred T cells (2, 3), their in vivo activity and potency can be thwarted by the complex immunosuppressive nature of the tumor microenvironment (4). Combination protocols incorporating checkpoint inhibitors (CPIs) such as anti-CTLA-4 or anti-PD-L1/PD-1 are currently being considered (NCT02408861; NCT02210117; NCT02374242; NCT02453620) but the potential exacerbation of the toxicities associated with CPIs may limit their implementation. Advanced genetic engineering of the ACT product offers a solution to the toxicity issues by specifically targeting tumor-reactive T cells rather than inducing systemic blockade of the inhibitory checkpoint. The protocols used for the generation of ACT are compatible with genetic manipulation of cells prior to transfer, which can be used to increase the proliferative capacity of lymphocytes (5), to prolong their in vivo persistence (6), to improve tumor infiltration (7) as well as to bypass tumor immune suppression.

Programmed Death-1 (PD-1, CD279) is one of the key co-inhibitory immune receptors expressed by activated T cells. Initially described on a T cell hybridoma undergoing cell death (8), PD-1 is a critical regulator of T cell responses and essential to the maintenance of peripheral self-tolerance (9). In mouse and human cancers, high levels of PD-1 are found on TILs, whilst its ligand (PD-L1) is upregulated by tumor and stromal cells in response to inflammatory cytokines (e.g. IFN-γ) (10, 11). The PDL-1/PD-1 axis plays a major role in tumor growth and immune escape through inhibition of T cell proliferation, effector function (12) and of T cell survival by
promotion of apoptosis (13). The administration of blocking anti-PD-1 or PDL-1 antibodies in vivo results in enhanced CD8$^+$ T cell responses and decreases tumor burden in mouse models of cancer (14, 15). In humans, expression of PD-1 by TILs is associated with impaired effector function and/or poor outcome in several tumor types (16, 17). Direct evidence supporting the importance of this pathway in modulating antitumor immunity comes from recent clinical trials in melanoma and non small cell lung cancer, where anti-PD-1 antibodies have improved both progression free and overall survival (18, 19). Of relevance, systemic immunotherapy with CPIs can also induce immune-related adverse events (irAEs). Specific ablation of negative regulators of T-cell function on tumor-reactive T cells used for ACT offers the potential to exploit the antitumor activity whilst reducing systemic toxicity.

Efficient and rapid inactivation of genes in primary antigen-specific T cells is achievable using the transient expression of transcription activator-like effector nucleases (TALEN) mRNA, which offers several safety advantages for clinical applications (20). Using two different mouse models of cancer, we defined the impact of TALEN-mediated PD-1 gene inactivation in adoptively transferred tumor-reactive CD4$^+$ and CD8$^+$ T cells. Our data supports a model in which PD-1 gene inactivation increases persistence of T cells at the tumor site, enhancing tumor control of B16 melanoma by gp-100-reactive CD8$^+$ T cells and mediating complete rejection of established MCA205 fibrosarcoma by endogenous CD4$^+$ and CD8$^+$ T cells. This work demonstrates both the feasibility and the potential potency of strategies incorporating Immune Checkpoint Editing (ICE) of tumor-reactive T cells for use in the context of adoptive T cell therapies for cancer.
Materials and Methods

Mice and cell lines

6- to 8-week-old pmel-1/SJL TCR-transgenic, C57BL/6 and C57BL/6-SJL mice were purchased from Charles River Laboratories Kent. All animal use was in accordance with the Home Office guidelines. The B16.BL6 melanoma cell line was obtained from Prof James Allison, the MCA205 fibrosarcoma cell line was provided by Prof Guido Kroemer, EL4 thymoma cells were provided by Prof Henning Walczak and authentication was performed by the ATCC using short tandem repeat DNA profiles. The cells were grown in RPMI-1640 supplemented with 10% FCS, L-glutamine, Pen/Strept (Sigma-Aldrich).

TALEN construction and validation

Three pairs of TALEN targeting the PD-1 murine gene were produced by Cellectis using the solid phase assembly method (21). Their activity was evaluated in 5x10^6 EL4 cells, co-transfected with 10 μg of *in vitro* transcribed mRNA (mMESSAGE mMACHINE T7 Kit, Ambion) from each half TALEN (Fig. S1). Three days post transfection, locus specific PCRs were performed on genomic DNA. (Table S1), mutations were assessed by mismatches digestion (T7) and Miseq analysis (20).

Cell culture and adoptive transfer

Splenocytes and lymph nodes cells from pmel-1/SJL transgenic mice were cultured in complete RPMI with gp100 peptide (Pepceuticals) and rhIL-2 (Preprotech) 100UI/mL for 24h prior to selection of CD8^+^ T cells using Dynabeads FlowComp Mouse CD8 kit. TRL were selected from 100-150mm^3^ tumors using Dynabeads FlowComp Mouse Pan T (CD90.2) and maintained in complete RPMI with rhIL-2 (1000UI/mL). 5x10^6 Pmel-1 CD8^+^ T cells and MCA205 TRL/180 μL of BTX medium T were mixed with 20 μg of IVT mRNA, prior to electroporation using an Agile Pulse BTX system.
(Harvard Apparatus). C57BL/6 mice were subcutaneously implanted with either $2.5 \times 10^5$ B16 cells or $4 \times 10^5$ MCA205 cells (day 0). On day 6 for the pmel-1 model and on day 4 for the MCA205 model, total body irradiation (TBI) was performed (5 Gy) and $1 \times 10^6$ pmel-1 T cells or $1 \times 10^6$ MCA205 TRL were adoptively transferred into tumor-bearing mice ($n = 5$ per group), followed by intraperitoneal (i.p.) injection of rhIL-2 ($1.2 \times 10^6$ IU) for 3 days. Mice were sacrificed when the tumors exceeded 15 mm in diameter. Mice were treated with the anti-mouse CD8a 2.43 depleting antibody (BioXcell) and the anti-MCH class II M5/114 (BioXcell), i.p. on day 0, 2, 4, 6, 8 after ACT (10 mg/kg).

**Flow cytometry**

Tumors were weighed, digested in collagenase D (Roche) and mechanically disaggregated through 70-μm filters. Lymph nodes cells and lymphocytes from tumor samples, enriched on a Ficoll gradient were incubated with murine antibodies: anti-CD4-V500 (BD Horizon), anti-CD8-BV650, anti-PD-1-PE-Cy7 (Biolegend), anti-CD45.1-APC-Cy7, anti-FoxP3-AF700, anti-IFN-γ-FITC (re-stimulation with gp100-pulsed dendritic cells for pmel cells or PMA/ionomycin for TRL), anti-KI67-PerCP-eFluor 710, Fixable Viability Dye eFluor 450 (eBioscience), anti-FLICA (Vybrant FAM Poly Caspases Assay Kit, ThermoFisher), annexin-V-PE Apoptosis Detection Kit II (BD Pharmingen), Cell Sorting Set-up Beads (Life Technologies), and anti-human Granzyme B-APC (Invitrogen) in a blocking solution: 5% mouse serum, 5% rat serum (Thermoscientific), 2% FCS, 2% anti-FcR 2.4G2 (BioXcell). Samples were permeabilized using a Fixation/Permeabilization kit (eBioscience), acquired on a LSRII Fortessa and analysed with FlowJo software (Tree-Star).

**Western blot analysis**

Proteins were separated and subjected to the following antibodies: anti-TALEN
(1mg/ml), anti-GAPDH (D16H11) (Cell signaling, 1:2000), HRP-coupled secondary antibody anti-Rabbit IgG1 HRP-linked (Cell signaling).

**Statistical analysis**

One-way ANOVA, two-way ANOVA or \( t \) tests with \( P < 0.05 \) were performed using Prism 6.0 software (GraphPad). Multiple comparisons were corrected with the Bonferroni coefficient and Kaplan-Meier survival curves were compared with the log-rank test.

*For additional information, see supplemental data section*

**Results and Discussion**

**TALEN-mediated PD-1 gene inactivation in melanoma reactive CD8\(^+\) pmel-1 T cells increases persistence of CD8\(^{PD-1Ex1}\) pmel-1 cells at the tumor site**

Three pairs of TALENs targeting the murine PD-1 gene were tested in EL4 cells using an optimized mRNA-electroporation protocol. Only the pair targeting the exon 1 sequence (**Fig. 1A**) caused detectable mismatch-identified mutagenesis (up to 27%) in the PD-1 gene, correlating with loss of PD-1 expression in up to 15% of electroporated EL4 cells (Supplementary **Fig. S1**). To investigate whether PD-1 inactivation of primary tumor-reactive T cells provided superior antitumor activity against the poorly immunogenic mouse melanoma B16 model, we used CD8\(^+\) T cell receptor transgenic (TCR Tg) cells specific to the melanoma differentiation antigen gp-100 (pmel-1, Supplementary **Fig. S2A**) (22). *In vitro* activated pmel-1 T cells were electroporated with control GFP mRNA (CD8\(^{wt}\)) or PD-1-targeting TALEN mRNA (CD8\(^{PD-1Ex1}\)), delivering a high transfection efficiency of >85% as confirmed by GFP expression (Supplementary **Fig. S2B**). Western blot analysis confirmed transient TALEN expression one day (d1) after transfection (**Fig.1B**) and Miseq analysis of the targeted sequence showed a high frequency of mutations (53% non-homologous end
joining (NHEJ)) (Fig. 1C). Three days after transfection, PD-1 negative cells were enriched using magnetic beads (Supplementary Fig. S2C) prior to ACT of 1x10^6 CD8^{wt} or CD8^{PD-1Ex1} pmel-1 cells and rhIL-2 into B16 tumor-bearing mice. Significantly enhanced tumor control was consistently observed in mice receiving CD8^{PD-1Ex1} cells compared to those treated with CD8^{wt} cells (Fig. 1D). Six days after transfer in vivo, a significant enrichment of tumor-infiltrating PD-1 negative pmel-1 cells was observed in mice treated with CD8^{PD-1Ex1} T cells (48.2%) (Fig. 1E upper panel), which contributed to a 2-fold increase in the total number of tumor-infiltrating pmel-1 cells (Fig. 1E lower panel). In contrast, the absolute number of T cells in draining lymph nodes (DLNs) was similar between the two groups, suggesting that accumulation of CD8^{PD-1Ex1} T cells at the tumor site was not due to differences in engraftment nor infiltration from the DLNs (Supplementary Fig. S2D). Whereas use of RNA and electroporation to deliver TALENs is compatible with future clinical translation, it does not allow incorporation of a reporter gene to distinguish PD-1 edited cells. Nevertheless, the rate of mutagenesis, investigated ex-vivo 7 days after ACT demonstrates an effective PD-1 gene editing (70%) in the PD-1 negative fraction from the CD8^{PD-1Ex1} group (Supplementary Fig. S2E). To investigate the mechanisms underpinning enhanced tumor control by pmel-1 cells in the CD8^{PD-1Ex1} group, we characterized the proliferation and effector functions of CD8^{wt} and CD8^{PD-1Ex1} T cells in both PD-1^+ and PD-1^- tumor-infiltrating pmel-1 populations. Contrary to previous work suggesting that PD-1 signaling reduces effector activity at the tumor site (23), no differences were observed in KI67, granzyme B (GZB) or interferon-γ (IFN-γ) expression between PD-1^+ and PD-1^- cells. When we compared the adjusted percentages (% of cells in PD-1^+ and PD-1^- sub-populations) of tumor-infiltrating KI67^+, GZB^+ and IFN-γ^+ cells, we observed that the TALEN-induced PD-1 gene
inactivation did not impact the proliferative or functional characteristics of pmel-1 CD8⁺T cells in vivo (Supplementary Fig. S2F, G, H). Instead, we consistently observed the appearance of a PD-1⁻ pmel-1 population in the CD8⁺PD-1Ex1 group, which contributed to an increase in the total number of KI67⁻, GZB⁻ and IFN-γ⁻ expressing cells in tumors from mice receiving CD8⁺PD-1Ex1 T cells (Fig. 1F, G). Together these data strongly suggest that, at least in the context of ACT, PD-1 expression primarily controls number of tumor-reactive T cells at the tumor site rather than their proliferative or functional status.

**PD-1 gene inactivation of polyclonal tumor-reactive lymphocytes (TRL) promotes persistence of activated CD4⁺ and CD8⁺ at the tumor site**

To define the therapeutic potential and functional impact of PD-1 gene inactivation in a more physiologically relevant T cell population, we conducted the PD-1 gene editing of polyclonal tumor-reactive lymphocytes (TRL) from C57BL/6SJL mice, challenged with MCA205 cells (24). CD4⁺ and CD8⁺ T-cells were isolated from the tumor (TILs) and one tumor-draining lymph node (TDLN) via positive selection. After electroporation of the donor TRL, we observed a transfection efficiency >65% and we identified TALEN-induced PD-1 gene mutations by Miseq analysis in 26% of CD4⁺ T cells and almost 40% of CD8⁺ T cells (Supplementary Fig. S3A, B).

In parallel to the generation of the donor mock transfected (TRLwt) and PD-1 edited TRL cells (TRLPD-1Ex1), we challenged a separate group of C57BL/6 mice with MCA205 tumors. Four days later, tumor-bearing mice were treated with TBI followed by ACT with TRLwt or TRLPD-1Ex1 cells and rhIL-2. Six days after transfer, analysis of PD-1 expression on TILs from mice receiving TRLwt or TRLPD-1Ex1 revealed a 15-20% average increase in PD-1⁻ CD4⁺ and PD-1⁻ CD8⁺ T cells (Fig. 2A, B). Consistent with our findings in the TCR Tg model, a significant accumulation of PD-1⁻ cells was
observed only at the tumor site (Fig. 2C, S3C). Whilst PD-1 gene inactivation did not alter TRL proliferation (KI67) or function (GZB and IFN-γ) (Supplementary Fig. S3D, E, F), the absolute number of PD1− TRL expressing KI67, GZB and IFN-γ was significantly higher in mice receiving TRL^{PD-1EX1} (Fig. 2D, E, F).

Given that the increase in the number of PD-1− cells in mice receiving TRL^{PD-1EX1} cells was not associated with increased proliferation, we evaluated whether this could be explained by a reduced rate of PD-1-induced death. Using annexin-V and a fluorescent caspase substrate kit (FLICA), we observed an overall reduction in the frequency of intra-tumoral apoptotic cells in PD-1− compared to PD-1+ CD4+ and CD8+ T cells (Fig. 3A, B, D, E). Whereas we observed no difference in the frequency of apoptotic cells between mice treated with TRL^{wt} and TRL^{PD-1EX1}, a significant increase in the absolute number of annexin-V− and FLICA− TRL^{PD-1EX1} cells per mg of tumor was reported (Fig. 3C, F). The data suggest that instead of increasing T cell reactivity against tumors, TRL^{PD-1EX1} cells are rendered resistant to PD-1-mediated cell death at the tumor site.

**PD-1 gene-inactivation drives CD4 and CD8 dependent rejection of established tumors and long-term memory**

PD-1-gene inactivation significantly increased the activity of our ACT protocol (p=0.0052) and anti-tumor activity was dependent on both CD8+ and CD4+ T cells as administration of depleting anti-CD8 or MHC-II blocking antibodies ablated anti-tumor responses (Fig. 4A, B). No evidence of tumor recurrence was observed after MCA205 rechallenge on day 50 in mice that had previously rejected tumors (data not shown). The development of long-term memory, as demonstrated by protection against a subsequent tumor challenge, is an important feature of successful T cell adoptive immunotherapy (25). Our data show high levels of KI67, consistent with
high proliferative capacity for both TRL and TRL\textsuperscript{PD-1EX1} cells, which also displayed a T-bet\textsuperscript{hi} CD62L\textsuperscript{low}CD44\textsuperscript{hi} phenotype consistent with effector memory T cells (Supplementary Fig. S4A,B) (27). Finally, \textit{ex-vivo} stimulation of circulating T cells from surviving mice (40 days after tumor rejection) demonstrated high levels of IFN-\(\gamma\) production in both TRL and TRL\textsuperscript{PD-1EX1} groups arguing against terminal differentiation (Supplementary Fig. S4C) (28).

In summary, our data demonstrate the feasibility of application of clinically relevant gene-editing approaches, conferring superior \textit{in vivo} activity in the context of adoptive cell therapy protocols. In both tumor models, mice well tolerated the ACT with no evidence of toxicity (weight, physiological alterations). To the best of our knowledge this is the first proof of concept study illustrating enhancement and persistence of antitumor responses using targeted genome editing of primary tumor reactive T cells. Our data indicate that the primary mechanism by which PD-1 gene inactivation affects tumor-reactive T cells is by regulating their ability to survive rather than increasing their activity on a per cell basis, which aligns with the original description of the role of PD-1 signaling as a pro-apoptotic factor (8). Whilst we investigated PD-1 as the initial proof of concept target, the technology and approach described potentially allows the permanent disruption of one or more other inhibitory checkpoints, conferring a considerable advantage to the design the next generation of cancer immunotherapies.

\textbf{Authors' Contributions}

\textbf{Conception and design}: L. Menger, SA. Quezada, KS. Peggs

\textbf{Development of methodology}: L. Menger

\textbf{Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.)}: L. Menger, A. Sledzinska, K. Bergerhoff, FA. Vargas,
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): L. Menger, A. Sledzinska, J. Herrero

Writing, review, and/or revision of the manuscript: L. Menger, SA. Quezada, KS. Peggs

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): L. Menger, J. Smith, L. Poirot

Study supervision: SA. Quezada and KS. Peggs

Grant Support
S.A.Q. is funded by a CRUK Career Development Fellowship and a Cancer Research Institute Investigator Award. K.S.P. receives funding from CRUK, Leukaemia and Lymphoma Research. This work was funded in part by an EU FP7 grant and undertaken at UCL Hospitals/UCL which received support from the Department of Health and CRUK funding schemes for NIH Biomedical Research Centres and Experimental Cancer Medicine Centres.

References and Notes


Figure legends

Fig. 1: TALEN-mediated PD-1 gene inactivation in pmel-1 CD8+T cells enhances the antitumor activity of ACT. (A) Schematic representation of murine Pdcd1 gene (chr. 1) and TALEN targeted sequence (exon 1). (B) TALEN protein expression at day 1, 2, 3 after transfection. (C) TALEN-induced mutagenesis (>50%) by Misseq analysis of CD8^{PD-1Ex1} pmel-1 T cells. NHEJ: non-homologous end joining. (D) B16 tumor growth curve in mice receiving 1x10^6 CD8^{wt} cells or CD8^{PD-1Ex1} ACT, 6 days after tumor challenge. (E) PD-1 expression on tumor-infiltrating CD8+ T cells and transferred cells engraftment at the tumor site. (F, G) Proliferation (Ki67) and functional analysis of tumor-infiltrating CD8^{wt} cells or CD8^{PD-1Ex1} depicting GZB and IFN-γ expressions. Each dot represents an individual mouse, and histograms represent mean ± SD of 2 independent experiments (n=10), two-way ANOVA (**P<0.01; ***P<0.001).

Fig. 2: Functional analysis of ACT with PD-1 gene inactivation on TRL 6 days after transfer in vivo. (A) Flow plots depicting PD-1 expression on TRL^{wt} or TRL^{PD-1-Ex1} T cells. (B) Percentage of PD-1+ cells showing an average of 15-20% increase on TRL^{PD-1-Ex1} compared to TRL^{wt} T cells. (C) Absolute number of PD1+ and PD1− TRL^{wt} and TRL^{PD-1-Ex1} T cells per mg of tumor. (D, E, F) Representative flow plots showing Ki67-, GZB- and IFN-γ-expressions on CD4+ and CD8+ TRL^{wt} and TRL^{PD-1-Ex1} T cells and absolute number of cells per mg of tumor. Each dot plot represents an individual mouse, and histograms represent mean ± SD of 3 independent experiments (n=15). Non-parametric t test (B), two-way ANOVA (C, E, F) *P<0.05, **P<0.01, ***P<0.001.

Fig. 3: PD-1 regulates the survival of adoptively transferred TRL in vivo. (A, D) Representative histograms depicting the annexin-V/FLICA positivity in PD-1+ and PD-1− TRL 6 days after ACT. (B, E) Adjusted percentage of annexin-V+/FLICA+
cells in PD-1+ and PD-1− subsets of CD4+ and CD8+ TRL wt and TRL PD-1Ex1 T cells. Histograms represent mean ± SD from 2 independent experiments (n=10). (C, F) Absolute numbers of annexin-V/FLICA− CD4+ and CD8+ TRL per mg of tumor. Two-way ANOVA (B), and multiple comparison one-way ANOVA with Bonferroni correction (C) **P<0.01, ***P<0.001.

Fig. 4: Therapeutic efficacy of ACT with PD-1 gene inactivation of TRL on MCA205 fibrosarcoma. (A) MCA205 growth curve after ACT with TRL and CD8 depleting or MHC-II blockade antibodies. Two-way ANOVA *P<0.05, **P<0.01. (B) Treatment with TRL PD-1Ex1 resulted in significant prolongation of survival (n=15). Log-rank test, P=0.0052. Depletion of CD8+ subset or MHC-II blockade abrogates the TRL PD-1Ex1 cells–induced antitumor effects (n=10).